Risultati della ricerca - Jean‐Pierre Bronowicki
- Mostra 1 - 20 risultati su 55
- Vai alla pagina seguente
-
1
The Challenge of Prognosis and Staging for Hepatocellular Carcinoma di Jorge A. Marrero, Masatoshi Kudo, Jean-Pierre Bronowicki
Pubblicazione 2010Revisão -
2
-
3
-
4
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study di Shannon Ferrante, Jagpreet Chhatwal, Clifford A. Brass, Antoine C. El Khoury, Fred Poordad, Jean-Pierre Bronowicki, Elamin H. Elbasha
Pubblicazione 2013Artigo -
5
-
6
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin di M. Diago, Mitchell L. Shiffman, Jean‐Pierre Bronowicki, Stefan Zeuzem, M. Rodríguez‐Torres, S. Chris Pappas, Andreas Tietz, David R. Nelson
Pubblicazione 2010Artigo -
7
The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges di Marie Müller, Vincent Haghnejad, Marion Schaefer, Guillaume Gauchotte, Bénédicte Caron, Laurent Peyrin‐Biroulet, Jean-Pierre Bronowicki, Cindy Neuzillet, Anthony Lopez
Pubblicazione 2022Revisão -
8
-
9
Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year Study of 127 French Patients di Jean‐Pierre Bronowicki, Denis Vetter, F Dumas, Karim Boudjéma, Robert Bader, Anne-Marie Weiss, Jean-Jacques Wenger, P Boissel, Marc‐André Bigard, Michel Doffoël
Pubblicazione 1994Artigo -
10
Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections di Graham R. Foster, Christophe Hézode, Jean‐Pierre Bronowicki, Giampiero Carosi, Ola Weiland, Lieselotte Verlinden, Rolf van Heeswijk, Ben Van Baelen, Gastón Picchio, Maria Beumont
Pubblicazione 2011Artigo -
11
Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France di Jean‐Baptiste Chevaux, Abdelbasset Nani, Abderrahim Oussalah, Véronique Venard, Mouni Bensenane, Arthur Belle, Jean‐Louis Guéant, Marc‐André Bigard, Jean-Pierre Bronowicki, Laurent Peyrin–Biroulet
Pubblicazione 2009Artigo -
12
Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection di Olivier Hermine, François Lefrère, Jean‐Pierre Bronowicki, Xavier Mariette, Katayoun Jondeau, Virginie Eclache-Saudreau, B Delmas, Françoise Valensi, P. Cacoub, Christian Bréchot, Bruno Varet, Xavier Troussard
Pubblicazione 2002Artigo -
13
Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy di Jean‐Pierre Bronowicki, Véronique Venard, C. Botté, Nathalie Monhoven, Isabelle Gastin, Laurence Choné, Hervé Hudziak, Bertrand Rhin, Christophe Delanoë, Alain Lefaou, Marc‐André Bigard, P Gaucher
Pubblicazione 1997Artigo -
14
Primary Lymphoma of the Liver: Clinical–Pathological Features and Relationship With Hcv Infection in French Patients di Jean‐Pierre Bronowicki, Catherine Bineau, Pierre Feugier, Olivier Hermine, Nicole Brousse, Frédéric Oberti, Marie-Christine Rousselet, Sébastien Dharancy, Philippe Gaulard, Jean–François Fléjou, Dominique Cazals–Hatem, Eric Labouyrie
Pubblicazione 2003Artigo -
15
869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results Fr... di Eric Lawitz, Xavier Forns, Stefan Zeuzem, Edward Gane, Jean‐Pierre Bronowicki, Pietro Andreoné, Andrzej Horban, Ashley Brown, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk‐Mahadevan, Ronald Kalmeijer, Maria Beumont‐Mauviel
Pubblicazione 2013Artigo -
16
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+) di Vincent Leroy, Peter Angus, Jean‐Pierre Bronowicki, Gregory J. Dore, Christophe Hézode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee, Rafia Bhore, M.J. Jimenez-Exposito, Alexander Thompson
Pubblicazione 2016Artigo -
17
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3... di Jason Grebely, Stefan Mauss, Ashley Brown, Jean‐Pierre Bronowicki, Massimo Puoti, David Wyles, Macky Natha, Yanni Zhu, Junming Yang, Bruce Kreter, Diana M. Brainard, Chohee Yun, Val Carr, Gregory J. Dore
Pubblicazione 2016Artigo -
18
Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy di Stella Maris Martínez, Juliette Foucher, Jean-Marc Combis, Sophie Métivier, Maurizia Rossana Brunetto, Dominique Capron, Marc Bourlière, Jean‐Pierre Bronowicki, Thông Dao, M. Maynard-Muet, Damien Lucidarme, Wassil Merrouche, Xavier Forns, Victor de Lédinghen
Pubblicazione 2012Artigo -
19
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B di Patrick Marcellin, Herve Momméja-Marin, Stephen L. Sacks, George Lau, D. Séréni, Jean‐Pierre Bronowicki, Brian Conway, Christian Trépo, Robert M. Blum, Byung Chul Yoo, Elsa Mondou, J. Sorbel, A. Lynn Snow, Franck Rousseau, Hyo‐Suk Lee
Pubblicazione 2004Artigo -
20
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial di Mark S. Sulkowski, Marc Bourlière, Jean-Pierre Bronowicki, Tarik Asselah, Jean‐Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Schérer, Gerhard Nehmiz, Gerhard Steinmann, Wulf O. Böcher
Pubblicazione 2013Artigo
Strumenti per la ricerca:
Soggetti correlati
Medicine
Internal medicine
Gastroenterology
Virus
Hepatitis C virus
Immunology
Hepatitis C
Ribavirin
Biology
Hepatocellular carcinoma
Virology
Cirrhosis
Gene
Genotype
Oncology
Genetics
Pathology
Boceprevir
Adverse effect
Alternative medicine
Cancer
Chronic hepatitis
Cohort
Hepatitis B virus
Physics
Placebo
Sofosbuvir
Surgery
Biochemistry
Daclatasvir